243448-16-0

Usage

Uses

Used in Pharmaceutical Synthesis:
6,8-Difluoro-4-hydroxyquinoline is used as a key intermediate in the synthesis of various pharmaceuticals, leveraging its unique structural features to contribute to the development of novel therapeutic agents.
Used in Agrochemical Development:
In the agrochemical industry, 6,8-Difluoro-4-hydroxyquinoline is utilized as an intermediate for the creation of new pesticides, capitalizing on its potential antimicrobial and antifungal properties to enhance crop protection.
Used in Antimicrobial Applications:
6,8-Difluoro-4-hydroxyquinoline is employed as an antimicrobial agent, particularly for its ability to combat a range of microbial infections, due to its inherent activity against bacteria and fungi.
Used in Antifungal Applications:
6,8-DIFLUORO-4-HYDROXYQUINOLINE is also used as an antifungal agent, harnessing its properties to treat and prevent fungal infections, making it valuable in both medical and agricultural settings.
Used in Oncology Research:
6,8-Difluoro-4-hydroxyquinoline is used in oncology research for its moderate cytotoxicity against cancer cell lines, offering potential in the discovery and development of new anticancer drugs.
Used in Drug Development:
6,8-DIFLUORO-4-HYDROXYQUINOLINE is utilized in drug development efforts, focusing on its potential to be modified and optimized for targeted cancer therapies and other therapeutic applications.

InChI:InChI=1/C9H5F2NO/c10-5-3-6-8(13)1-2-12-9(6)7(11)4-5/h1-4H,(H,12,13)

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 367-25-9 2,4-difluorophenylamine 
• 372-39-4 3,5-difluoroaniline 
• 1071541-70-2 5-[(3,5-difluoro-phenylamino)-methylene]-2,2-dimethyl-[1,3]dioxane-4,6-dione 

Downstream Products

• 577692-34-3 4-bromo-6,8-difluoroquinoline 
• 1384272-31-4 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(5-fluoro-2-methylphenyl)urea 
• 1384272-32-5 1-(2-chloro-5-(trifluoromethyl)phenyl)-3-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)urea 
• 1384272-33-6 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(4-isopropylphenyl)urea 
• 1384272-34-7 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(3,4-dimethylphenyl)urea 
• 239463-89-9 4-chloro-6,8-difluoro-quinoline 
• 1384272-25-6 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(2-(trifluoromethoxy)phenyl)urea 
• 1384272-26-7 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(4-(trifluoromethoxy)phenyl)urea 
• 1384272-27-8 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(2-(trifluoromethyl)phenyl)urea 
• 1384272-28-9 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(4-(trifluoromethyl)phenyl)urea 
• 1384272-29-0 1-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)-3-(2-fluorophenyl)urea 
• 1384272-30-3 1-(3-chloro-2-fluorophenyl)-3-(2-((6,8-difluoroquinolin-4-yl)amino)ethyl)urea 

Relevant academic research and scientific papers

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

Synthesis, anti-inflammatory and antimicrobial evaluation of novel N1-(quinolin-4yl)ethane-1,2-diamine phenyl urea derivatives

A series of substituted N-(quinolin-4-yl)ethanediamine phenyl urea derivatives of biological interest were prepared by sequential quinoline synthesis, chlorination, and substitution reaction followed by reaction of resulting amine with different aryl isoc

AURORA KINASE MODULATORS AND METHOD OF USE

The present invention relates to chemical compounds having a general formula I {INSERT STRUCTURE HERE} wherein A1-8, D,, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

Assembly of 4-aminoquinolines via palladium catalysis: A mild and convenient alternative to SNAr methodology

4-Aminoquinolines, classically prepared via SNAr chemistry from an amine and 4-haloquinoline, are important scaffolds in medicinal chemistry. Interest in these compounds prompted us to explore palladium catalysis as an alternative to the existing methods for their preparation. Initial results followed by an iterative screening paradigm confirmed Pd(OAc)2/ DPEphos/K3PO4 as a mild and convenient alternative for the formation of the C-N bond in 4-aminoquinolines. A description of the screen and the scope of this methodology are discussed herein.

Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities

A simple two-step synthesis method was used to make 51 B-ring-substituted 4-hydroxyquinolines allowing analysis of the effect of ring substitutions on inhibition of growth of chloroquine sensitive and resistant strains of Plasmodium falciparum, the dominant cause of malaria morbidity. Substituted quinoline rings other than the 7-chloroquinoline ring found in chloroquine were found to have significant activity against the drug-resistant strain of P. falciparum W2.